“These results show that inhibitory CARs have very interesting and underappreciated properties that can improve the performance of immune cell therapies,” said Wilson Wong, Ph.D., Professor of ...
Researchers developed the first genome-wide CRISPR screening tool for primary human natural killer (NK) cells Study revealed critical regulators of NK cell activity that can be targeted to improve ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
A new approach engineers immune cells to recognize byproducts of cancer cells to trigger migration toward the tumor.
ImmunityBio Inc. (NASDAQ:IBRX) is one of the 10 Must-Watch Stocks Right Now. ImmunityBio surged by 7.29 percent on Friday to finish at $8.39 apiece, as investors took heart from the company’s optimism ...
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural ...
Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research ...
In a study that further corroborated these observations, scientists found that cyclic fasting in mice improved their antitumor responses mediated by natural killer (NK) cells. 4 The results, published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results